Trials / Completed
CompletedNCT01787669
Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema
A Multicentre Clinical Trial of Switching Between Intravitreal Bevacizumab (Avastin®) and Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema (SwitchDMO)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- University of Sydney · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The specific aim of the study is to test the following hypothesis: That switching between treatments from bevacizumab to Ozurdex or vice versa in eyes with diabetic macular oedema with no or incomplete response from one therapy is beneficial.
Detailed description
A Multicentre Clinical Trial of Switching Between Intravitreal Bevacizumab (Avastin®) and Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema (SwitchDMO)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avastin (Bevacizumab) | Avastin (Bevacizumab) administered intravitreally |
| DRUG | Ozurdex (dexamethasone) | Ozurdex (dexamethasone) given intravitreally |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2017-01-01
- Completion
- 2017-10-01
- First posted
- 2013-02-08
- Last updated
- 2018-11-13
Locations
3 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT01787669. Inclusion in this directory is not an endorsement.